212 related articles for article (PubMed ID: 29479832)
21. Guidelines on the management of osteoporosis associated with chronic liver disease.
Collier JD; Ninkovic M; Compston JE
Gut; 2002 Feb; 50 Suppl 1(Suppl 1):i1-9. PubMed ID: 11788576
[No Abstract] [Full Text] [Related]
22. An Overview of the Molecular Mechanisms Contributing to Musculoskeletal Disorders in Chronic Liver Disease: Osteoporosis, Sarcopenia, and Osteoporotic Sarcopenia.
Yang YJ; Kim DJ
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807573
[TBL] [Abstract][Full Text] [Related]
23. [Alcoholic osteopathy].
Sarli M; Plotkin H; Zanchetta JR
Medicina (B Aires); 1994; 54(4):363-70. PubMed ID: 7715435
[TBL] [Abstract][Full Text] [Related]
24. [Osteoporosis].
Ziegler R
Schweiz Rundsch Med Prax; 1994 Sep; 83(38):1051-5. PubMed ID: 7939067
[TBL] [Abstract][Full Text] [Related]
25. Serum sclerostin in alcoholics: a pilot study.
González-Reimers E; Martín-González C; de la Vega-Prieto MJ; Pelazas-González R; Fernández-Rodríguez C; López-Prieto J; Alvisa-Negrín J; Santolaria-Fernández F
Alcohol Alcohol; 2013; 48(3):278-82. PubMed ID: 23296214
[TBL] [Abstract][Full Text] [Related]
26. [Bone metabolism in non-cholestatic chronic hepatopathy].
González Sanz-Agero P; Muñoz Núñez F; Erdozaín Sosa JC; Garrido Cantarero G; Coya Viña J; Sánchez Cabezudo MJ; Martínez Gómez ME
Med Clin (Barc); 1998 Oct; 111(12):446-50. PubMed ID: 9842530
[TBL] [Abstract][Full Text] [Related]
27. Sclerostin and Bone Aging: A Mini-Review.
Hay E; Bouaziz W; Funck-Brentano T; Cohen-Solal M
Gerontology; 2016; 62(6):618-623. PubMed ID: 27177738
[TBL] [Abstract][Full Text] [Related]
28. Risk of secondary osteoporosis due to lobular cholestasis in non-cirrhotic primary biliary cholangitis.
Seki A; Ikeda F; Miyatake H; Takaguchi K; Hayashi S; Osawa T; Fujioka SI; Tanaka R; Ando M; Seki H; Iwasaki Y; Yamamoto K; Okada H
J Gastroenterol Hepatol; 2017 Sep; 32(9):1611-1616. PubMed ID: 28114749
[TBL] [Abstract][Full Text] [Related]
29. Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis.
Morales-Santana S; Díez-Pérez A; Olmos JM; Nogués X; Sosa M; Díaz-Curiel M; Pérez-Castrillón JL; Pérez-Cano R; Torrijos A; Jodar E; Rio LD; Caeiro-Rey JR; Reyes-García R; García-Fontana B; González-Macías J; Muñoz-Torres M
Maturitas; 2015 Dec; 82(4):402-10. PubMed ID: 26358930
[TBL] [Abstract][Full Text] [Related]
30. Genetic variation in Wnt/β-catenin and ER signalling pathways in female and male elite dancers and its associations with low bone mineral density: a cross-section and longitudinal study.
Amorim T; Durães C; Machado JC; Metsios GS; Wyon M; Maia J; Flouris AD; Marques F; Nogueira L; Adubeiro N; Koutedakis Y
Osteoporos Int; 2018 Oct; 29(10):2261-2274. PubMed ID: 29978256
[TBL] [Abstract][Full Text] [Related]
31. Bone disorders in chronic liver diseases.
Luxon BA
Curr Gastroenterol Rep; 2011 Feb; 13(1):40-8. PubMed ID: 21104208
[TBL] [Abstract][Full Text] [Related]
32. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
33. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
Catalano A; Morabito N; Basile G; Brancatelli S; Cucinotta D; Lasco A
J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142
[TBL] [Abstract][Full Text] [Related]
34. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus.
Gaudio A; Privitera F; Battaglia K; Torrisi V; Sidoti MH; Pulvirenti I; Canzonieri E; Tringali G; Fiore CE
J Clin Endocrinol Metab; 2012 Oct; 97(10):3744-50. PubMed ID: 22855334
[TBL] [Abstract][Full Text] [Related]
35. [Wnt pathway and sclerostin as new targets for assessment and treatment of osteoporosis].
Alonso G; García-Martín A; Muñoz-Torres M
Med Clin (Barc); 2012 Dec; 139(14):634-9. PubMed ID: 22613824
[TBL] [Abstract][Full Text] [Related]
36. Management of osteoporosis in adults with cystic fibrosis.
Hecker TM; Aris RM
Drugs; 2004; 64(2):133-47. PubMed ID: 14717616
[TBL] [Abstract][Full Text] [Related]
37. Polymorphisms in key bone modulator cytokines genes influence bisphosphonates therapy in postmenopausal women.
Lima CA; Javorski NR; Souza AP; Barbosa AD; Valença AP; Crovella S; Souza PR; De Azevedo Silva J; Sandrin-Garcia P
Inflammopharmacology; 2017 Apr; 25(2):191-201. PubMed ID: 28220389
[TBL] [Abstract][Full Text] [Related]
38. Treatment of osteoporosis in renal insufficiency.
Schipper LG; Fleuren HW; van den Bergh JP; Meinardi JR; Veldman BA; Kramers C
Clin Rheumatol; 2015 Aug; 34(8):1341-5. PubMed ID: 25630310
[TBL] [Abstract][Full Text] [Related]
39. [Bone and Nutrition. Sclerostin and bone metabolism].
Tatsumi S; Nagamoto K; Ogata M; Miyamoto K
Clin Calcium; 2015 Jul; 25(7):1043-7. PubMed ID: 26119318
[TBL] [Abstract][Full Text] [Related]
40. Bad to the bone: the effects of liver diseases on bone.
Marignani M; Angeletti S; Capurso G; Cassetta S; Delle Fave G
Minerva Med; 2004 Dec; 95(6):489-505. PubMed ID: 15785434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
